AUTHORS
Tomas Rivero Equiza, MD, Laura Palomo, PhD2, Pablo Castillo Jimenez3, Mireia Morgades4, Liseth Belinda Cifuentes, MD5, Montserrat Arnan Sangerman Sr, PhD6, Helena Pomares Sr, MD, PhD7, Laura Segura De La Torre8, Marta Gomez Nuñez, MD9, Francisca Asis Maria Hernandez Mohedo10, Marisa Calabuig, PhD11, Carme Talarn12, Félix López-Cadenas13, Alejandro Avendaño Pita14, Ana Yeguas Bermejo, MD15, Lucia Moreno Mur16, Raquel De Paz Arias, MD17, Joaquin Breña, PhD18, Paula Cadenas Alonso19, Teresa Bernal, MD, PhD20, Jordi Vila Bou21, Marta Sitges Arriaga22, Gemma Azaceta Reinares23, Jose Antonio Queizan Hernandez, MD24, Eugènia Rivero25, Josefa Esperanza Marco Buades26, Tzu Hua Chen, MD27, Montserrat Cortes, MD28, Ana Alfonso-Pierola, MD29, Joan Bargay, MD, PhD30, Marta Callejas, PhD31, Ruth Stuckey, PhD32, Almudena Fernández Gonzalez33, Sara García-Ávila, MD34, Maria Angeles Perez Saenz35, Miquel Díaz36, Alba Mesa37, Isabel Granada38, Rebeca Jurado Tapiador39, Lurdes Zamora, PhD40, Blanca Xicoy, PhD41
AFFILIATIONS
1 Institut Catalá d'Oncologia, Badalona, Spain, Josep Carreras Research Institute, Badalona, Spain
2 Institut Catalá d'Oncologia, Badalona, Spain
3 Institut Catalá d'Oncologia, Badalona, Spain, Josep Carreras Research Institute, Badalona, Spain
4 Institut Catalá d'Oncologia, Badalona, Spain, Josep Carreras Research Institute, Badalona, Spain
5 Institut Català d'Oncologia Bellvitge, Barcelona, Spain
6 Institut Català d'Oncologia Bellvitge, Barcelona, Spain
7 Institut Català d'Oncologia Bellvitge, Barcelona, Spain
8 Hospital Universitario Parc Taulí, Sabadell, Spain
9 Hospital Universitario Parc Taulí, Sabadell, Spain
10 Hospital Universitario Virgen de las Nieves, Granada, Spain
11 Hospital Clínico Universitario de Valencia, Valencia, Spain
12 Hospital de Tarragona Joan XXIII, Tarragona, Spain
13 Hospital Universitario Vall d'Hebron, Barcelona, Spain
14 Hospital Universitario de Salmamanca, Salamanca, Spain
15 Hospital Clínico Universitario de Valadolid, Valladolid, Spain
16 Hospital Universitario La Paz, Madrid, Spain
17 Hospital Universitario La Paz, Madrid, Spain
18 Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain
19 Hospital Universitario de León, León, Spain
20 Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain
21 Institut Catalá d'Oncologia Girona, Girona, Spain
22 Institut Catalá d'Oncologia Girona, Girona, Spain
23 Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
24 Hospital General Universitario de Segovia, Segovia, Spain
25 Hospital Universitari Arnau de Vilanova, Lleida, Spain
26 Hospital Universitario Doctor Peset, Valencia, Spain
27 Hospital General Universitario Morales Meseguer, Murcia, Spain
28 Hospital Sant Joan de Deu-Fundacio Althaia, Manresa, Spain
29 Clínica Universidad De Navarra, Pamplona, Spain
30 Hospital Universitario Son LLatzer, Mallorca, Spain
31 Hospital Universitario Príncipe de Asturias, Madrid, Spain
32 Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain
33 Hospital Universitario de Cabueñes, Gijón, Spain
34 Hospital del Mar, Barcelona, Spain
35 Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
36 Hospital Universitari Mútua de Terrassa, Barcelona, Spain
37 Institut Catalá d'Oncologia, Badalona, Spain
38 Institut Catalá d'Oncologia, Badalona, Spain
39 Institut Catalá d'Oncologia, Badalona, Spain
40 Institut Catalá d'Oncologia, Badalona, Spain, Josep Carreras Research Institute, Badalona, Spain
41 Institut Catalá d'Oncologia, Badalona, Spain, Josep Carreras Research Institute, Badalona, Spain
ABSTRACT
Introduction
Several prognostic scoring models integrating clinical, hematologic and molecular variables have been developed for chronic myelomonocytic leukemia (CMML) to improve risk stratification, yet their comparative performance and the incremental value of inflammatory biomarkers remain uncertain. Inflammation is a hallmark of CMML and contributes to disease biology, particularly in the myeloproliferative (MP) phenotype. The Triple-A score, a prognostic model incorporating inflammation-related features and validated in chronic myeloid neoplasms, has not been evaluated in CMML. Although the recently developed OPIC score (Objective Prognostic Index for CMML) incorporates the monocyte-to-lymphocyte ratio (MLR), the added prognostic value of inflammatory biomarkers beyond currently available CMML prognostic models has not been explored. Therefore, we aimed to compare the currently available prognostic scores developed for CMML in a real world series and assess whether inflammatory biomarkers improve their prognostic performance.
Methods
Adult patients (pts) (≥18 years) diagnosed with CMML according to the 2022 WHO and ICC classifications and with next-generation sequencing (NGS) data at diagnosis were included. Prognostic performance of IPSS-M, CPSS, CPSS-Mol, BLAST, BLAST-Mol, iCPSS, OPIC and Triple-A was evaluated, as well as continuous inflammatory indices including neutrophil/lymphocyte ratio (NLR), neutrophil/monocyte ratio (NMR), MLR and platelet/lymphocyte ratio (PLR).
Model discrimination and prediction accuracy were assessed using Harrell`s C index and the Integrated Brier Score (IBS). The incremental prognostic value of inflammatory indices beyond each prognostic score was evaluated using multivariable Cox models and likelihood ratio tests (LRT).
Results
A total of 413 pts were included between December 2007 and February 2026. Median age was 73 years (range, 41–91); 68% were male. CMML-1 and Myelodysplastic (MD) subtype accounted for 86% and 77% of cases, respectively, and 16% had oligomonocytic CMML. TET2, SRSF2 and ASXL1 mutations were present in 66%, 36%, and 36% of pts, respectively. Median NLR was 1.90, NMR 2.04, MLR 0.88 and PLR 69. Median follow-up among alive pts was 22 months; median overall survival (OS) was 5.1 years (95%CI 4–6.3) and 5- year cumulative incidence of acute myeloid leukemia (AML) progression was 19% (95%CI 13–25%).
Compared with MD- CMML, MP CMML displayed higher inflammatory indices, higher frequency of ASXL1 (56 vs 30%) and NRAS (30 vs 7,5%) mutations, and significantly shorter OS (median 2.3 vs 6.2 years; p<0.001).
All evaluated prognostic models (IPSS-M, CPSS, CPSS-Mol, iCPSS, BLAST, BLAST-Mol, Triple-A and OPIC) significantly stratified OS. Discriminatory performance varied across models, with BLAST-Mol (0.70), OPIC (0.70), IPSS-M (0.70) and BLAST (0.69) showing the highest Harrell's C-index values. According to the IBS, BLAST-Mol (0.147), BLAST (0.150) and OPIC (0.155) showed the best predictive performance, whereas Triple-A showed the poorest overall performance (highest IBS and lowest Harrell's C-index). Despite this,Triple-A significantly discriminated OS in MD-CMML after grouping patients into low/int-1 and int-2/high-risk categories.
In univariable analysis, higher NLR, NMR and MLR were associated with inferior OS, whereas PLR was not. After adjustment for each prognostic model, NLR and MLR consistently retained independent prognostic significance. According to LRT, addition of NLR provided significantly incremental value (p≤0.007) and improved C- index of IPSS-M (0.74), BLAST (0.73), BLAST-Mol (0.73), and CPSS, CPSS-Mol and iCPSS, whereas MLR improved all evaluated models (p≤0.003). In contrast, NMR and PLR provided limited incremental value.
Conclusions
Among contemporary CMML prognostic models, BLAST-Mol showed the best overall predictive performance, while the clinically based BLAST score achieved comparable predictive performance despite not incorporating molecular variables. Nevertheless, current prognostic models do not fully capture the prognostic impact of systemic inflammation in CMML. Addition of the simple and universally available inflammatory biomarkers MLR and NLR consistently provides incremental prognostic information beyond contemporary prognostic models and significantly improves their predictive performance. These readily available biomarkers should be considered in the development of future CMML risk stratification systems.
DISCLOSURES
Tomas Rivero Equiza, MD: Astellas - Honoraria; GSK - Honoraria; Abbvie - Honoraria; GSK - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)